Marinomed Biotech AG (VIE:MARI)
Austria · Delayed Price · Currency is EUR 19.90
-0.05 (-0.25%)
Oct 3, 2025, 5:35 PM CET
Marinomed Biotech AG Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 9.51 | 4.75 | 9.06 | 11.28 | 11.63 | 8.12 | Upgrade |
Other Revenue | 0.25 | 0.05 | 0.34 | 0.47 | - | - | Upgrade |
| 9.76 | 4.79 | 9.4 | 11.74 | 11.63 | 8.12 | Upgrade | |
Revenue Growth (YoY) | 47.40% | -49.01% | -19.96% | 1.00% | 43.12% | 20.43% | Upgrade |
Cost of Revenue | 3.29 | 3.77 | 8.08 | 9.4 | 10.43 | 8.92 | Upgrade |
Gross Profit | 6.47 | 1.03 | 1.32 | 2.35 | 1.2 | -0.79 | Upgrade |
Selling, General & Admin | 4.31 | 4.83 | 5.05 | 5.13 | 4.83 | 4.37 | Upgrade |
Other Operating Expenses | 3.71 | 2.75 | 1.83 | 1.83 | 1.42 | 1.39 | Upgrade |
Operating Expenses | 8.41 | 8.02 | 7.34 | 7.63 | 6.86 | 6.18 | Upgrade |
Operating Income | -1.93 | -6.99 | -6.01 | -5.28 | -5.66 | -6.98 | Upgrade |
Interest Expense | -0.6 | -0.96 | -1.38 | -2.51 | -1.51 | -0.71 | Upgrade |
Interest & Investment Income | - | - | - | 0.04 | 0.06 | 0.05 | Upgrade |
Currency Exchange Gain (Loss) | 0 | 0 | 0 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 0.01 | -0.18 | 0.04 | 1.11 | -0.04 | 0.53 | Upgrade |
EBT Excluding Unusual Items | -2.53 | -8.13 | -7.35 | -6.64 | -7.15 | -7.1 | Upgrade |
Gain (Loss) on Sale of Investments | 0 | - | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 0 | 0 | 0 | - | - | - | Upgrade |
Asset Writedown | -0.65 | -0.65 | - | - | - | - | Upgrade |
Other Unusual Items | -6.74 | -6.74 | 0.99 | 0.24 | 1.45 | 1.1 | Upgrade |
Pretax Income | 9 | -15.52 | -6.36 | -6.39 | -5.69 | -6.01 | Upgrade |
Income Tax Expense | -0.12 | -0.1 | 0 | 0.01 | 0.2 | 0 | Upgrade |
Net Income | 9.12 | -15.42 | -6.37 | -6.4 | -5.89 | -6.01 | Upgrade |
Net Income to Common | 9.12 | -15.42 | -6.37 | -6.4 | -5.89 | -6.01 | Upgrade |
Shares Outstanding (Basic) | 2 | 2 | 2 | 1 | 1 | 1 | Upgrade |
Shares Outstanding (Diluted) | 2 | 2 | 2 | 1 | 1 | 1 | Upgrade |
Shares Change (YoY) | 17.17% | 17.14% | 1.29% | 1.56% | 0.31% | 3.75% | Upgrade |
EPS (Basic) | 5.13 | -8.67 | -4.19 | -4.27 | -3.99 | -4.09 | Upgrade |
EPS (Diluted) | 5.13 | -8.67 | -4.19 | -4.30 | -4.00 | -4.10 | Upgrade |
Free Cash Flow | -0.8 | -2.4 | -3.7 | -5.43 | -5.79 | -10.85 | Upgrade |
Free Cash Flow Per Share | -0.45 | -1.35 | -2.44 | -3.62 | -3.92 | -7.37 | Upgrade |
Gross Margin | 66.33% | 21.40% | 14.07% | 20.00% | 10.32% | -9.77% | Upgrade |
Operating Margin | -19.81% | -145.90% | -63.97% | -44.99% | -48.67% | -85.88% | Upgrade |
Profit Margin | 93.41% | -321.66% | -67.72% | -54.48% | -50.67% | -73.98% | Upgrade |
Free Cash Flow Margin | -8.20% | -50.08% | -39.37% | -46.24% | -49.75% | -133.53% | Upgrade |
EBITDA | -1.57 | -6.58 | -5.56 | -4.89 | -5.28 | -6.79 | Upgrade |
EBITDA Margin | -16.09% | -137.28% | -59.15% | -41.66% | -45.42% | -83.62% | Upgrade |
D&A For EBITDA | 0.36 | 0.41 | 0.45 | 0.39 | 0.38 | 0.18 | Upgrade |
EBIT | -1.93 | -6.99 | -6.01 | -5.28 | -5.66 | -6.98 | Upgrade |
EBIT Margin | -19.81% | -145.90% | -63.97% | -44.99% | -48.67% | -85.88% | Upgrade |
Revenue as Reported | 0.1 | 0.1 | 1.49 | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.